WNT3A and persistent truncus arteriosus: The overall findings suggest that MAT treatment may serve as a potential therapeutic approach for inhibiting TAC‐induced atrial electrical and structural remodelling by suppressing Wnt3a/β‐catenin signalling pathways, thereby reducing susceptibility to AF.